Literature DB >> 19190334

Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.

Laura N Burga1, Nadine M Tung, Susan L Troyan, Mihnea Bostina, Panagiotis A Konstantinopoulos, Helena Fountzilas, Dimitrios Spentzos, Alexander Miron, Yosuf A Yassin, Bernard T Lee, Gerburg M Wulf.   

Abstract

Female BRCA1 mutation carriers have a nearly 80% probability of developing breast cancer during their life-time. We hypothesized that the breast epithelium at risk in BRCA1 mutation carriers harbors mammary epithelial cells (MEC) with altered proliferation and differentiation properties. Using a three-dimensional culture technique to grow MECs ex vivo, we found that the ability to form colonies, an indication of clonality, was restricted to the aldehyde dehydrogenase 1-positive fraction in MECs but not in HCC1937 BRCA1-mutant cancer cells. Primary MECs from BRCA1 mutation carriers (n = 9) had a 28% greater ability for clonal growth compared with normal controls (n = 6; P = 0.006), and their colonies were significantly larger. Colonies in controls and BRCA1 mutation carriers stained positive for BRCA1 by immunohistochemistry, and 79% of the examined single colonies from BRCA1 carriers retained heterozygosity for BRCA1 (ROH). Colonies from BRCA1 mutation carriers frequently showed high epidermal growth factor receptor (EGFR) expression (71% EGFR positive versus 44% in controls) and were negative for estrogen receptor (ERalpha; 32% ER negative, 44% mixed, 24% ER positive versus 90% ER positive in controls). Expression of CK14 and p63 were not significantly different. Microarray studies revealed that colonies from BRCA1-mutant PMECs anticipate expression profiles found in BRCA1-related tumors, and that the EGFR pathway is up-regulated. We conclude that BRCA1 haploinsufficiency leads to an increased ability for clonal growth and proliferation in the PMECs of BRCA1 mutation carriers, possibly as a result of EGFR pathway activation. These altered growth and differentiation properties may render BRCA1-mutant PMECs vulnerable to transformation and predispose to the development of ER-negative, EGFR-positive breast cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190334      PMCID: PMC3041511          DOI: 10.1158/0008-5472.CAN-08-2954

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.

Authors:  Matt van de Rijn; Charles M Perou; Rob Tibshirani; Phillippe Haas; Olli Kallioniemi; Juha Kononen; Joachim Torhorst; Guido Sauter; Markus Zuber; Ossi R Köchli; Frank Mross; Holger Dieterich; Rob Seitz; Doug Ross; David Botstein; Pat Brown
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex.

Authors:  Paul Pavlidis; Jie Qin; Victoria Arango; John J Mann; Etienne Sibille
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

3.  Genetic analysis of BRCA1 function in a defined tumor cell line.

Authors:  R Scully; S Ganesan; K Vlasakova; J Chen; M Socolovsky; D M Livingston
Journal:  Mol Cell       Date:  1999-12       Impact factor: 17.970

4.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures.

Authors:  Jayanta Debnath; Senthil K Muthuswamy; Joan S Brugge
Journal:  Methods       Date:  2003-07       Impact factor: 3.608

5.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

6.  Estrogen receptors alpha and beta in the rodent mammary gland.

Authors:  S Saji; E V Jensen; S Nilsson; T Rylander; M Warner; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

7.  Expression of the telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor beta growth inhibition in p16INK4A(-) human mammary epithelial cells.

Authors:  M R Stampfer; J Garbe; G Levine; S Lichtsteiner; A P Vasserot; P Yaswen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

8.  Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis.

Authors:  Gerburg Wulf; Priti Garg; Yih-Cherng Liou; Dirk Iglehart; Kun Ping Lu
Journal:  EMBO J       Date:  2004-07-15       Impact factor: 11.598

9.  Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue.

Authors:  O W Petersen; P E Høyer; B van Deurs
Journal:  Cancer Res       Date:  1987-11-01       Impact factor: 12.701

10.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Authors:  Timothy R Rebbeck; Tara Friebel; Henry T Lynch; Susan L Neuhausen; Laura van 't Veer; Judy E Garber; Gareth R Evans; Steven A Narod; Claudine Isaacs; Ellen Matloff; Mary B Daly; Olufunmilayo I Olopade; Barbara L Weber
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

View more
  42 in total

1.  Antitumor Agents. 282. 2'-(R)-O-acetylglaucarubinone, a quassinoid from Odyendyea gabonensis as a potential anti-breast and anti-ovarian cancer agent.

Authors:  Yoshihide Usami; Kyoko Nakagawa-Goto; Jing-Yu Lang; Yoon Kim; Chin-Yu Lai; Masuo Goto; Nobuko Sakurai; Masahiko Taniguchi; Toshiyuki Akiyama; Susan L Morris-Natschke; Kenneth F Bastow; Gordon Cragg; David J Newman; Mihoyo Fujitake; Koichi Takeya; Mien-Chie Hung; Eva Y-H P Lee; Kuo-Hsiung Lee
Journal:  J Nat Prod       Date:  2010-09-24       Impact factor: 4.050

Review 2.  A continuum model for tumour suppression.

Authors:  Alice H Berger; Alfred G Knudson; Pier Paolo Pandolfi
Journal:  Nature       Date:  2011-08-10       Impact factor: 49.962

3.  Time-lapse imaging of primary preneoplastic mammary epithelial cells derived from genetically engineered mouse models of breast cancer.

Authors:  Rebecca E Nakles; Sarah L Millman; M Carla Cabrera; Peter Johnson; Susette Mueller; Philipp S Hoppe; Timm Schroeder; Priscilla A Furth
Journal:  J Vis Exp       Date:  2013-02-08       Impact factor: 1.355

4.  Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.

Authors:  Ashish Juvekar; Hai Hu; Sina Yadegarynia; Costas A Lyssiotis; Soumya Ullas; Evan C Lien; Gary Bellinger; Jaekyoung Son; Rosanna C Hok; Pankaj Seth; Michele B Daly; Baek Kim; Ralph Scully; John M Asara; Lewis C Cantley; Gerburg M Wulf
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-08       Impact factor: 11.205

5.  Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.

Authors:  Hiroyuki Konishi; Morassa Mohseni; Akina Tamaki; Joseph P Garay; Sarah Croessmann; Sivasundaram Karnan; Akinobu Ota; Hong Yuen Wong; Yuko Konishi; Bedri Karakas; Khola Tahir; Abde M Abukhdeir; John P Gustin; Justin Cidado; Grace M Wang; David Cosgrove; Rory Cochran; Danijela Jelovac; Michaela J Higgins; Sabrina Arena; Lauren Hawkins; Josh Lauring; Amy L Gross; Christopher M Heaphy; Yositaka Hosokawa; Edward Gabrielson; Alan K Meeker; Kala Visvanathan; Pedram Argani; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

6.  HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype.

Authors:  Penney M Gilbert; Janna K Mouw; Meredith A Unger; Johnathon N Lakins; Mawuse K Gbegnon; Virginia B Clemmer; Miriam Benezra; Jonathan D Licht; Nancy J Boudreau; Kelvin K C Tsai; Alana L Welm; Michael D Feldman; Barbara L Weber; Valerie M Weaver
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

7.  BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.

Authors:  Da Li; Na-Na Chen; Ji-Min Cao; Wu-Ping Sun; Yi-Ming Zhou; Chun-Yan Li; Xiu-Xia Wang
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.

Authors:  Da Li; Fang-Fang Bi; Na-Na Chen; Ji-Min Cao; Wu-Ping Sun; Yi-Ming Zhou; Chun-Yan Li; Qing Yang
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations.

Authors:  Alfonso Bellacosa; Andrew K Godwin; Suraj Peri; Karthik Devarajan; Elena Caretti; Lisa Vanderveer; Betsy Bove; Carolyn Slater; Yan Zhou; Mary Daly; Sharon Howard; Kerry S Campbell; Emmanuelle Nicolas; Anthony T Yeung; Margie L Clapper; James A Crowell; Henry T Lynch; Eric Ross; Levy Kopelovich; Alfred G Knudson
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

10.  Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.

Authors:  Nadine Tung; Yihong Wang; Laura C Collins; Jennifer Kaplan; Hailun Li; Rebecca Gelman; Amy H Comander; Bridget Gallagher; Katharina Fetten; Karen Krag; Kathryn A Stoeckert; Robert D Legare; Dennis Sgroi; Paula D Ryan; Judy E Garber; Stuart J Schnitt
Journal:  Breast Cancer Res       Date:  2010-02-11       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.